ABSI
Absci Corp
NASDAQ · Healthcare · Biotechnology · US
$8.54
+3.52%Oct 13, 2026, 12:00 UTC
Absci announced that it will report business updates and third-quarter 2026 financial and operating results before market open on November 12, 2026.
Source:Sep 24, 2026, 12:00 UTC
Absci announced preliminary details for its Phase 2 STORYLINE trial of AI-designed antibody ABS-201 for endometriosis, with initiation anticipated in mid-2027.
Source:Sep 10, 2026, 19:56 UTC
Eli Lilly is making strategic investments in outside companies such as Absci Corp., which is developing an experimental endometriosis therapy, as part of its expansion into women's health.
Source:Aug 11, 2026, 20:05 UTC
Absci completed a $100 million underwritten offering, including a $40 million strategic investment from Eli Lilly and Company.
Source:Aug 11, 2026, 20:05 UTC
Absci Corporation reported financial and operating results for the second quarter of 2026.
Jun 25, 2026, 15:26 UTC
Absci released positive interim data from its Phase I hair loss study for ABS-201, showing the drug is well tolerated and supports infrequent dosing.
Source:Jun 24, 2026, 20:01 UTC
Eli Lilly invested $40 million in Absci for equity, leading a $50 million funding round.
Source:Jun 24, 2026, 11:55 UTC
Absci Corporation priced a $100 million underwritten offering to support clinical development.